Amount Raised
$100 Million
Round Type
Series C
WalthamBiotechnologyHealth CareMedicalTherapeuticsDescription
TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies in oncology, today announced the closing of an oversubscribed $100 million Series C financing. The financing round added new investors including funds and accounts managed by BlackRock, RA Capital Management, and two undisclosed healthcare-focused funds. Existing investors including founding investor Longwood Fund, 6 Dimensions Capital, Bessemer Venture Partners, GV, Novartis Venture Fund and Pitango HealthTech also participated in the round. Proceeds from this financing will be used to advance TScan’s TCR-T cell therapy pipeline for solid and liquid tumors into the clinic.
Who to call at TScan Therapeutics, Inc., and when
A new round usually means TScan Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day TScan Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at TScan Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at TScan Therapeutics, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment TScan Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
TScan Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.